Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma

NCT05978050 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

354

Enrollment

OTHER

Sponsor class

Conditions

Gastric or Esophagogastric Junction Adenocarcinoma

Interventions

DRUG: nimotuzumab plus paclitaxel
DRUG: placebo plus paclitaxel

Sponsor

Biotech Pharmaceutical Co., Ltd.